We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Aspirin Reduces Cancer Risk by Restricting cAMP Production

By Biotechdaily staff writers
Posted on 14 Jul 2003
Researchers have found that the anticancer properties of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are due to their inhibition of the enzyme cyclo-oxygenase-2 (COX-2), which results in lowered production of cyclic adenosine monophoshate (cAMP), an inhibitor of apoptosis.

One of the earliest molecular events in 80% of colon cancers is overexpression of COX-2, a rate-limiting enzyme of prostaglandin (PG) production. More...
Prior studies have shown that long-term use of NSAIDs inhibits COX-2 and is associated with a 40-50% reduction in the incidence of colon cancer. In a new study published July 1, 2003, in the online edition of the Proceedings of the National Academy of Sciences, investigators at the University of California, San Diego (USA; www.ucsd.edu), identified the specific site where NSAIDs have a regulatory effect on apoptosis.

The study found that increased COX-2 activity caused the major PGE2 receptors on epithelial cells, EP2 and EP4, to increase cAMP production, which promotes growth and inhibits apoptosis in some cell types. Furthermore, substances that stimulated cAMP synthesis such as PGE2, cholera toxin, and a membrane-permeant cAMP analog, protected normal and transformed intestinal epithelial cells from apoptosis. This protection was associated with cAMP-mediated, rapid induction of cellular inhibitor of apoptosis protein (c-IAP)-2.

The authors concluded, "These results help to explain the cancer chemoprotective effects of nonsteroidal anti-inflammatory drugs by defining a mechanism through which cAMP signaling can promote the development of colorectal and possibly other epithelial cancers by means of disruption of normal apoptotic processes.”



Related Links:
University of California, San Diego

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.